OVID · CIK 0001636651 · operating
Ovid Therapeutics is a biopharmaceutical company focused on developing treatments for epilepsies and seizure-related neurological disorders. The company's pipeline includes OV329, a GABA-AT inhibitor in Phase 1 development for drug-resistant epilepsies in adult and pediatric populations, and OV350, a small molecule KCC2 transporter activator also in Phase 1 trials for epilepsy treatment. The company is also advancing programs targeting psychosis in neurodevelopmental and Lewy body disease populations, as well as OV888, a selective ROCK2 inhibitor currently in Phase 1testing.
Ovid maintains collaboration and licensing agreements with established pharmaceutical and research organizations, including AstraZeneca, H. Lundbeck, Marinus Pharmaceuticals, Northwestern University, and Healx. These partnerships support the company's drug development efforts across its pipeline.
The company operates as a small-stage biopharmaceutical firm with 23 full-time employees and is headquartered in New York, NY. Ovid is incorporated in Delaware and trades on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | — | — | — | |
| 2023 | $-0.74 | $-0.74 | +3.9% | |
| 2022 | $-0.77 | $-0.77 | -143.8% | |
| 2021 | $1.76 | $1.78 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-11 | 0001628280-25-011844 | SEC ↗ |
| 2023-12-31 | 2024-03-08 | 0001628280-24-009809 | SEC ↗ |
| 2022-12-31 | 2023-03-13 | 0001628280-23-007648 | SEC ↗ |
| 2021-12-31 | 2022-03-15 | 0000950170-22-003668 | SEC ↗ |
| 2020-12-31 | 2021-03-15 | 0001564590-21-013016 | SEC ↗ |
| 2019-12-31 | 2020-03-11 | 0001564590-20-010108 | SEC ↗ |
| 2018-12-31 | 2019-03-07 | 0001564590-19-006804 | SEC ↗ |
| 2017-12-31 | 2018-03-29 | 0001564590-18-007152 | SEC ↗ |